<code id='0F1CB5CC15'></code><style id='0F1CB5CC15'></style>
    • <acronym id='0F1CB5CC15'></acronym>
      <center id='0F1CB5CC15'><center id='0F1CB5CC15'><tfoot id='0F1CB5CC15'></tfoot></center><abbr id='0F1CB5CC15'><dir id='0F1CB5CC15'><tfoot id='0F1CB5CC15'></tfoot><noframes id='0F1CB5CC15'>

    • <optgroup id='0F1CB5CC15'><strike id='0F1CB5CC15'><sup id='0F1CB5CC15'></sup></strike><code id='0F1CB5CC15'></code></optgroup>
        1. <b id='0F1CB5CC15'><label id='0F1CB5CC15'><select id='0F1CB5CC15'><dt id='0F1CB5CC15'><span id='0F1CB5CC15'></span></dt></select></label></b><u id='0F1CB5CC15'></u>
          <i id='0F1CB5CC15'><strike id='0F1CB5CC15'><tt id='0F1CB5CC15'><pre id='0F1CB5CC15'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:fashion    Page View:27825
          Senate Finance Committee Chair Ron Wyden (D-Ore.) Leah Millis/Pool via AP

          WASHINGTON — Senators on the Finance Committee on Wednesday nearly unanimously passed a bill to clamp down on drug middlemen, but kicked the can down the road on some of the more challenging policies.

          The bill would offer some more transparency into the business practices of pharmacy benefit managers, ensure PBMs aren’t skimming off of the money they send to insurers, prohibit them from overcharging insurers, and ensure certain fees in the Medicare program aren’t tied to a drug’s price.

          advertisement

          “It’s pretty hard to get 26 votes around here,” Finance Chair Ron Wyden (D-Ore.) said after the vote. “So we’re thrilled.”

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          FDA panel endorses Alnylam’s heart drug — after picking it apart
          FDA panel endorses Alnylam’s heart drug — after picking it apart

          KristofferTripplaar/SipaUSA/APAgroupofadviserstotheFoodandDrugAdministrationvotedinfavorofAlnylamPha

          read more
          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more

          FDA proposes changes to key medical devices approval pathway

          Lastweek,theFDAreleasedatrioofguidelinesclarifyingthewaytheyplantoevaluatedevicesthatgothroughthe510